One trial involving SSEA-1 in therapy used an antibody called FC-2.15, which was later determined to recognize the LeXepitope[259]. Mordoh et al. generated this IgM monoclonal antibody by immunizing Balb/c mice with tumor cells from an undifferentiated human primarybreast carcinoma[260]. FC-...
Background KIR3 DL2, an inhibitory receptor expressed by natural killer cells and a subset of normal CD8+ T cells, is aberrantly expressed in neoplastic cells in transformed mycosis fungoides and S茅zary syndrome. Anti- KIR3 DL2 targeted antibody therapy has shown potent activity in ...
The antibody conjugate drug brentuximab vedotin targets CD30. In clinical trials, brentuximab vedotin therapy improved clinical outcomes for relapsing and refractory classical HL (RR-cHL) patients by producing survival times that were 6 months longer than for patients on the conventional treatment arm ...
提要:目的观察芳维A酸乙酯(arotinoidethylester,AE)在HL260细胞分化成熟过程中对其CD11b、CD15表达的影响,初步探讨AE治疗脓疱型银屑病的可能机制。方法HL260细胞以二甲基亚砜(dimethylsulfoxide,DMSO)、全反式维A酸(all2trans2retinoicacid,ATRA)、AE诱导培养,5d后用流式细胞仪检测HL260细胞表面CD11b和CD15的表达。
目的:观察Bcl-2、CD10、CD34、CK15在基底细胞癌(BCC)和毛发上皮瘤(TE)中的表达,探讨其在两种肿瘤诊断和鉴别中的作用。方法:对确诊的36例BCC和16例TE石蜡包埋标本行Bcl-2、CD10、CD34、CK15免疫组化染色,观察其在肿瘤细胞及其周围间质中的表达。结果:在BCC和TE中表达的阳性率分别为Bcl-2(栅栏状模式):0、...
Inhibition of murine T cell-mediated cytolysis and T cell proliferation by a rat monoclonal antibody immunoprecipitating two lymphoid cell surface polypept... The monoclonal antibody methodology was used to identify membrane structures involved in T cell functions. To optimize chances to produce and ...
Elements Related to Heterogeneity of Antibody-Dependent Cell Cytotoxicity in Patients Under Trastuzumab Therapy for Primary Operable Breast Cancer Overexpr... Preliminary results from a pilot trial on trastuzumab's mechanism of action against operable breast tumors overexpressing Her2 suggested a role for ...
In this scenario, anti-TNF plus anti-TL1A combi- nation therapy may be beneficial, especially in those patients with high TNFa and TL1A levels. In addition, those CD patients who have become refractory to anti-TNFa therapies may use the TL1A pathway to bypass the need for TNFa to drive ...
However, with regard to PD-1/PD-L1 checkpoint blockade as monotherapy or in combination with other antitumor therapies, such as chemotherapy, radiotherapy (including conventional irradiation and stereotactic body radiotherapy), and target therapy, there are still many unknowns in treating patients with...
Abstract 2439: Cross-linker evaluation in the design of antibody-SN-38 conjugates for cancer therapy Antibody (MAb) conjugates of the potent topoisomerase I inhibitor, SN-38, prepared using the bifunctional derivative, 'CL2-SN-38' (maleimido-[x]-Phe-Lys-PABOCO-20-O-SN-38), were previously ...